ARWR - Earnings call transcript Q4 2017 | Arrowhead Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceutical's Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone

Liz. Thanks, everyone. afternoon, Good joining XXXX to ended fourth XXXX. for for September Arrowhead's its fiscal quarter us you discuss today results XX, Thank and year us CEO, President With management and from today Dr. are an overview Anzalone, will Christopher of who quarter; Dr. the provide and will Bruce of will of give clinical and a R&D, term Chief our financials. Head Ken Given, review near Operating Myszkowski, our Financial who Chief candidates our Officer discuss Officer, the who

call the to questions. up open then will We your

during statements Securities Arrowhead's made statements call to disclaims of XXE remind call. around of and without statements. XXXX, Act Before forward-looking other our and may All those These activities. Exchange you within contain and respect of our forward-looking we statements Arrowhead current Securities are Thus, begin, would any plans differ statements including inherently actual forward-looking statements, materially. comments undertakes candidates, limitation, results with certain than I Section like goals, that strategies, XXA Act Section today's and today's intent the uncertain. development, of meaning statements efficacy fact, discussed to XXXX. expected the projected of drug regarding of include to cash runway update expectations and of duty represent safety the the development and of on no are any These expectations management's future the historical

XX-K on call. turn Christopher of President call expected actual the cause be including over for to I’d to regard refer Chris? like CEO the XX-Q results considered to other from could Form report the presently should the considerations subsequent said, results You and and company. and this today's expressed annual quarterly factors in discussions risks that vary in risk to on Arrowhead's Company's under With matters additional the Form Dr. reports in Anzalone, that to

Christopher Anzalone

and moved forward decision and XXXX the ARC-AAT development has candidates ARC-XXX, productive to two a position generation difficult for from Phase That XXXX Phase to we company in drugs, afternoon been prior thank joining clinical delivery vehicle. a for to one Good stage EXX year Vince. preclinical Arrowhead, a overnight. an enormously everyone, very as from candidate Thanks, you utilize discontinue X and us today. ARC-XXX, a stage company X with moved of

In disclosed that given addition, not about investors for was new guidance getting lot and for uncertainty at Arrowhead had back a on timelines time clinic. the we not about much into there where platform was of going. Understandably, our

the of only but medal in makes We the company known are heels on of a clearly itself real face our adversity.

As we proud come look this am what back extraordinarily to accomplished of to we forward I is on company. and what

should enable the precision virus in and clinical treat pace in move a infection speed disease We are begin. from planned of disease competitive potentially We CTAs during liver us the CTA programs therapy cured going for planned clinical are the to XXXX QX, for next alpha-X These alpha-X to trials our quarters. to prior represent think CTA hepatitis two and ARO-AAT file two strategic to B ARO-HBV and real liver the with QX XXXX. and on programs HPV once begin a in chronic insights and as with advantages with

lung are filings hypertriglyceridemia are CTA for three an on three months. also and ARO-ANGX, for undisclosed ARO-LungX in ARO-APOCX, are against the the disease end XX treat CTAs These of all We target; schedule next to and file XXXX. additional around to planned

which formally referred We by Amgen XXXX clinical rapidly. or The $XX.X are moving $XXX million and with is was Amgen Amgen. candidate AMG-XXX may and additional eligible a nominated clinic this million the an (a) upfront initial receive to in our September called equity in now in against in addition, forward XXXX. milestone two One are and cardiovascular of Arrowhead investment ARO-LPA to and enter was previously LP we received which in potential (a) sometime been the anticipate target that equity deal In collaborations lipoprotein has as as payments announced payments.

are and So go zero how to breakouts five these have as in a possibly is the don’t to his drug biotech I XX changes the programs or next set of over planning potential this. believe, patients. The we from makeup XXXX table and XXXX candidates we clinical now I see seen company any ever dramatically, months. perform for do six company

us impact now and Let’s bit a look programs. these at a take

We September, The that two, manufacturing and moves TRiM host towards molecules what significantly is may of including platform technologies TRiM on a unveil RNAi and vehicles. platform costs, platform. to and we reduce risk of provides the we a inhaled ARC-AAT for reduced It more three, generations. profile. had we at good delivery improved intracellular accumulation, expect with step on rely as RNAi for on Arrowhead reduce longer decade ARO-AAT but targeted drug DPCs, of TRiM view be so example potential that expect These better research appears platform of activity, in administration, activity substantially to safety, believe day the the safety that not the metabolites built than subcutaneous injection and potent field routes does can also R&D we new new multiple do. than an a administration wider simplified we of TRiM because therefore several targeted margins of a safety a on previous duration smaller more builds all offers are an include they or TRiM actively of In First, one, evolutionary molecule advantages. maximal the retains prior generation delivery. simplicity, structural than

of program In gives addition, we us from ARC-AAT what the in learnt ARO-AAT. confidence much

in monthly ARO-AAT previous less non-human was should expect provide First, of potency would ARC-AAT this suppression hold hepatic sources AAT. of dosing potency to even our of for humans, generation in primates predictive we or of frequent compound near-complete

of similar it relates in guided volunteers as HBV least early our proof-of-concept of activity holds could for many was healthy in to this predict ARC-AAT, plans If Phase experiences X. knockdown at and prior with expectations patient’s. we programs ARO-HBV. to Similarly, our knockdown Second, have for

this We and have of other has RNAi cure Seroclearance hepatitis for and functional could that infection, always therapy been based chronic elusive well-tolerated mechanisms. sufficiently a drugs which and potent B enable believed s-antigen

case Heparc the open-label potential towards study. Our the has presented strengthened ARC-XXX last for importance conference of data we ARO-HBV the when from extension this week, at goal new [ph]

or multiple reduction viral coinciding that HBV achieved s-antigen show in an characterised entecavir, two in response. a ARC-XXX the patients receiving follow-up and we combination three with response patients host indicative including Specifically, with of host e-antigen of treatment and have of negative after markers study XXX positive e-antigen XX% in of increase by continued sustained ALT

sustained could a have possible this goal the even then So bodes virus these therapy is silence a DNA first fact well and its and only control When on be with ARO-HBV. favorable that integrated lead it’s arm a gene in should leaves in in continued production makes, tied critical RNAi only fighting ARC-XXX we own of has and to source marker the what if functional of clinical it results appears hepatitis forces a can the it does always B the something It deal. immune mind unchecked, fight care? this production. one virus was the DNA it on being of to If system zone. Well host to from ARC-XXX evidence was ARC-XXX host very the been one behind reached. that that big you is Therefore a back, part be to believed DNA type viral the integrated response ARO-HBV, why because after withdrawn, is This for thereby an this is that we in ARC-XXX host of our to was silence based everything demonstrated have have immunosuppressing enabled cure fact virus optimal that in approach immunosuppressive from into source enabled done context s-antigen. and cccDNA. that s-antigen by and was mean and reawakened, expression the keep of was overcome considering it targeting sub major to virus can

was against viral cccDNA since all substantially be Importantly, it hit to ARO-HBV DNA. specifically more transcripts integrated and both may active from designed mRNA s-antigen ARC-XXX,

have that are targets about programs, our hypertriglyceridemia optimistic and effectively announced our are disease be for therapies. risk C-III by to ARO-ANGX also newly factors validated new apolipoprotein independent cardiovascular addressed reason ARO-APOCX. are We traditional Angiopoietin-X not they and and

as cardiovascular internal these because addition are well, providing market smaller In to is development. strategies This market pathways partnering in in-house part or indications flexibility keeping orphan regulatory approaches. involve multiple could candidates that it and large associated offers important with for targets opportunities,

In specifically. example able the addressing silence forward technology flexibility the lung of of this as of the programs new have Finally, inhaled franchise TRiM we RNAi and host we for targeting program will open we believe is represent remains targets, animal that generally to for and view Arrowhead new TRiM good Once a itself. fundamentally a lung a capability been whose first models deeply validate we the lung target the administration, our opportunities. unto a lung platform undisclosed, targets multiple

additional Given, more now Head would the R&D. details call Bruce? to our on provide XXXX. to and like Dr. data With program COO as as well Bruce initial I that We over overview, will turn of in

Bruce Given

during and our the I I are the ARO-HBV us. therapeutic mentioned the areas are and candidate’s pace Today candidate. that ARO-HBV us each two since These quarters, provides three with just first go into focus and Chris we before Chris having confidence for over all very the programs and you, two they filings in end to get XXXX. current and exciting potential. on are pace anticipate shortly. Thank good and clinic the ARO- for of up AAT to rationale lead target afternoon on CTA CTAs The additional programs ARO-AAT data will then select want on were to for for everyone. that

or AAT export and start AAT damage, from and from inflammation have hepatocytes. with causes Let’s patients antitrypsin this can AAT for misfolded the that alpha-X to mutation does protein misfolded have lung lead downstream properly which first, of This low issues deficiency patient disorder; circulating be the disease. tissues not to ARO-AAT. levels that early-onset protein protects causes with involves a AAT The genetic two

and globules aggregates it polymers the is since Second, the inside cell. and the not properly then exported protein liver, into from accumulates

clearly protein, carcinoma provide that of early less virtually substantially and the just liver globules mid-stage right here. human to they production, what than when their replacement develop gone by gene had of disease, We weeks, In lung time and disease mutant so liver mice, which extensive that this placebo. get inflammatory They disease estimated it’s young progression, were They a is alpha-X we eliminate normal. lung a about. well. at for XXX,XXX studies deficiency less. their and back and attractive to therapies the we at We also, protein confirm globules, have had transgenic in but and disease There moved option XX-weeks but to to hepatocellular completed saw liver wanted are Treating hepatocellular parasites animals storage forms lot only disease like is protein functional RNAi really Z are they baseline, of baseline, improved do approved for confidence significant they approach carcinoma. that but which longer The the architecture mice liver, the less moderate they model have mechanism, also transplant. antitrypsin already for disease. older the but disease designation, the monomer were it’s AAT, out livers a had no we misfolded weeks long towards liver orphan very with the potential alpha-X to get had disease. more and the the There the polymer due around some mice cells. reduction inflamed which lot the way mice develop they globules, and with then mice, studied for AAT the is in older had human an halting is a is be aspects in we eight had So untreated a is that had disease in accumulation it based that a we also treated common than And against the ARX-AAT with protein, promise a at therapeutic protein we of RNAi We The Europe present more hepatocellular of disease produces and of recapitulates polymers doing mice, over diseases. several of would patients These intervened qualifies the hope. the and compressed in circulation done also a in had results deficiency. their humans. individual separate could models like treated a target. therapy just think one in later at fortunately, treated carcinoma. but with livers at U.S. Based In from mice no When treatment. result. globules clear mouse production in The the benefit from started has eight an care seen good in caused the older alpha-X possibly the very RNAi liver nuclei those baseline, it much during protein and they as so that is the numbers, and rare mice minimal on which was liver us work of demonstrated we had is one we treating secreting this

we monthly, of of liver, In prior near enable was and Keep dosing full also The knockdown we we’ve interval. even addition believe of produced to to our primates In ARC-AAT. in have ARO-AAT longer is with compound the the or clinical which outside down represents a AAT generation in so XX%. suppression also done XX% reduction AAT the looked effect about of long, in knock at liver Primates, duration we mind and of have over that a AAT circulating led mice, produced may bimonthly primates, protein. of experience XX% work circulating

mentioned, a we As Chris CTA XXXX. in intend for to QX, file ARO-AAT

and first one rapidly dose innovative single-dose We we multiple intended are clinic excited designed that have to study. study an is to data get in-human the back and into generate in

in design study this when initiated. discuss is will detail We this further

recently we the virus antigen, people be leading We therapies XXX therapy of body produces control. of XXX and the allow to protein believe on a system RNAi Arrowhead, response the lead to needs presented involves curative elusive. transcriptase. nukes, to to our the ARC-XXX HBV that to a experts. sustained everything been have capsid, or global and gene reverse cure estimated develop Now HBV, The for type polymerase, reduces sustained is functional infected surface that favorable new reducing addressed. is there inhibit health difficult and between that that from we care HBV fact standard HBV, analogues, clinical treat we have exerting be it nucleoside we ultimately are RNA, with million including represents chronically current that nothing pre-genomic HBV e-antigen based and clearly at here a nucleotide in the very is because that always believed virus of which my to may cure follow-up to viral infection the HBV possible. drugs that of treatment addition functional first and the class HBV, remains At some think evidence products, core large a but that reducing all. may I that a response body’s sorry, the proteins that good an of formed believe production of viral place approach immune host This reconstitute a just virus forms improve deeply go, is silence experts rates of sought we circulating lost to I’m all host chronic to to receive data in patients system no produces almost over at the and does access Many fully particles immune prevent problem

drugs HBV will central for treat role we therapy Because how to Also, RNAi do are off date effects ARO-HBV? a Just we seen RNAi because I likely with other approach, and the entire viruses, like most a We require combination any we reduced other an attacked acting that’s think, to stress these see inputs. nukes. and so like been transcriptome synergistic the going only HBV to difficult us important DNA. to direct on to s-antigen integrated enhanced already be the of drugs has address the way reduce have we coming RNAi by

wild So combination notably from RNAi opportunity best in to perspective, cure, doses achieving anybody our to an of function represents select a the plasmid than greater data reductions of present in than preclinical I recently regimen. ARO-HBV some wants three have in better logs quantization. chance greater of led possible on the had monotherapy the type of HBV This to who have ARO-HBV, logs mice, reductions three below in and HBV X.XX both level of s-antigen DNA logs respectively. dropped X.X of the e-antigen

the HBV this mutated and levels was HB duration simulate still models. active eight and we enough In intend much to high generate of and s-antigen affect model, two integrated to reduced to X study. logs, a relative addition, at weeks with led a we as was can s-antigen plan data eliminates approximately created of following dose by plasmid ARO-HBV the dose. to our patients these CTA in is site of first-in-human reduction encouraging HBV QX, ARO-AAT, We highly cccDNA. model a file dose was a single in and as that to DNA the by a ARO-HBV X.XX HBV Arrowhead single trigger In of like very XXXX This in multiple long logs

include to phase the of patients in the multiple HBV dose Importantly, we intend study. portion during X ascending

provide with the As further detail study we is initiated. will when ARO-AAT,

review to Arrowhead's our like will call I'd Ken? Now, CFO financials. Myszkowski, over Ken to turn who the

Ken Myszkowski

good Thank afternoon everyone. you and Bruce

of weighted loss fiscal Revenue payments $XXX,XXX XXXX. $X.XX was compared our per the XX.X with average for based was million driven on a compares is share share fiscal outstanding. As for outstanding net $X.XX weighted million collaboration XXXX. we based or by XX.X shares The reported per $XX.X the shares to received XXXX from million million fiscal a for for increase fiscal XXXX or $XX.X $XX.X Amgen. agreements today our loss with the million on net This upfront

were During with fiscal expenses and albeit $X.X $XX.X for expect the operating for related in ended XX, compared the year XXXX. XXXX, recognized XX, have fiscal year Total $XX.X balance XXXX ended operating to recognize Amgen million XXXX. cash million $XX.X to to for agreements we fiscal we used revenue fiscal XXXX. compared million million Net the million the in for XXXX in $XX.X September was activities September

payroll Our R&D to down of in declined workforce to due we although fiscal of General also million continued after and our primarily expense discontinuation clinical reduction and candidates expenses previous professional services November of in the a declined year, our declined due primarily the from clinical expenses. $XX.X candidates. quarter; to administrative million expenses last also the $XX.X put reduced to previous due discontinuation Salary into place expenses closed second

September of additional facility of research of to reflects cash out XX, our totalled $XX.X and as million Turning million million in in compared Madison. cash balance our the for cash The Amgen consisting used cash in our balance equity our and received primarily balance cash short $XX investment. XXXX operations payment new investments of million million million of $XX.X in and of at to expenditures September XX, to build from and in $XX.X term upfront $X.X $XX.X capital sheet $XX.X related ARO-LPA Offset XXXX. investments million our decrease by

brief With call to XX, the at turn overview, September million. shares was common that back XX.X Our XXXX I'll Chris.

Christopher Anzalone

Thanks, Ken.

to progress advantages. Transition we we believe and candidates XXXX amount have for we can we that up has TRiM drug transformational. XXXX of and where rapid to XXXX see in been five strong had be believe the platform expect an CTAs incredible file competitive calendar we’ve throughout is onto you set As

disease We antitrypsin first clinical the against with are to of alpha-X the this alpha-X quarter expect of only manifestation be and the deficiency in leaders clear candidate liver in company XXXX.

RNAi and enabling backbone in treatment on the believe in intellectual for therapeutic expect We we clinic real will to with We a HBV first functional therapy with are again the leaders chronic clear plan become the what be we HBV. leaders quarter back being second see in as in RNAi that cures. once of HBV a RNAi development chance of

for we for a RNAi Similarly, in and We the the and RNAi against are cardiovascular humans. we leaders that with the and use to humans. be expect by will Amgen disease file in Angiopoietin-X first RNAi use in ARO-ANGX, against CTAs XXXX believe developed LP(a) be end and will company to apolipoprotein first ARO-APOCX that of C-III to candidate we company

us We opens are RNAi other go also and now for a ways at in no in of company for lung to us capable present. targets. is leaders – diseases after This new enables chapter

badly to XXXX AAT in the approach will of we lot with for that go lung will are to first company candidate in be XXXX administration. after continue RNAi that with a we by where It only targets therapies believe expect non-clinical needed We assume data is experience and our additional certainly the is and diseases HBV, but patients. and viable using aggressive comfortable feel with safe against CTA these a also a we file and to will we given new end pipeline our high the inhaled This plans. by value to our disease build lung

to of patients. ultimately partners more open create address Operator? to has attract now. move sense to and up collaborations like now exciting for with we technology can medicines our we to the productive do we optimized get I new to makes to well the how to an at ability XXXX that to tissues, like so products questions. be may maximize to would to the we over call ability Amgen past are least TRiM our into did of programs. quality for look fast some It been of Therefore last believe for number a forward XXXX. positioned a variety has the your world target able we very we and The develop them all high were products it outstrips seen XX months, marketed Our potential year

Operator

William from [Operator Xu Instructions] Blair. with first the of line Katherine you. comes Our question Thank

now Your line is open.

Katherine Xu

Hello?

Christopher Anzalone

Hi, Katherine.

Katherine Xu

few I for Thank questions. good hi call. afternoon. the a Hi, have you

proof saw to incremental need just First, just future gather and with treatment XXXX? was concept for until we the most that ARO-HBV? good Any interesting data comment proof is that in think incremental information I the to or the given you you wondering my on to I – And treatment do And in see you the in think period will you [Indiscernible] we stop need understand you was tox during everything end, you. response do safety – of safety you to ARC-XXX, would concepts try information any any question the ARO-AAT very you therapeutic you down Are can second timing data year and on and see going talks safety you the lastly, what studies? the the of that is platform. provide, there important of Thank on very the large respond? is, Can then GLP side, keep treating aspects? at and for new removal the other the apparently that would [Indiscernible] this margin

Christopher Anzalone

me, know three if Okay, let here. of the so I help me forget any

and to we’ll patients here you powerful that. drug it’s ARO-HBV is to to bears integrated other to so that be So be to ARC-XXX. with question. down to that not a about the to just – to s-antigen that coming out knocking after ARO-HBV was if ample DNA, to program case got down But s-antigen x had body well to going cccDNA of have think that’s is for way know the it’s have know. a first That humans, for bring level in knock as we That’s – ARC-XXX. sustained We’ll where respect down more as to the s-antigen answer as in take the see, a to host a with a so continue effective the we going designed as antigens we treatment over. a needing if intention goal follow now well both than shot discontinue and good right can see and it’s is and out to stop to just the question to are certainly is treat don’t see We because response able going of that

that’s at dose to that just it body for of answer period certain possible to we our be needs now right it the for jolt, this – are that just the and know of removing don’t therapy what now. we we a the point plan but plan see Could going right and time it’s so see. to So is that

guidance The don’t second a just filed can we to question we data. Once much then have because concept when and you are also HBV know. for once is our I will think point know granular start patients that actually Once relating dosing let that proof dosing. we’ll we too to want CPAs we to AAT. call when and guidance those we you dosing we this at give more relating think on data think about are don’t know to start we of let we patients, I going start we give we can

we just until it. think to wait that for I then best it’s can us So talk and about happens

protocols give us to early really ensure that reasonable read we need can As mentioned, on think that good there time. approved we’ve those would regulators we but outs, start are that and protocols I at potential a Bruce got by

we’ll So point. DPCs. with more respect anything final as the expect with platform soon to let as on know margin safety much then have than the you with new know And don’t at say TRiM safety, do we We that. as to wider we one this

good so now where right margin expect tox GLP the We see clinic once do and certainly safety to with wide go we’ll are that we talks finished that’s whole in we and a are, platform. but

Operator

Elemer of question the line from Cantor. Instructions] [Operator comes next Our Piros with

open. Your line is now

Elemer Piros

more could HBV I design this me to afternoon, wondering it in against Good gentlemen. against version the DNA. if of understand RNAi that help the efficacious what is integrated you makes even was new maybe

Christopher Anzalone

Bruce, as you do walk the here, sequences want Thanks, broadly? through where least Elemer. to at

Bruce Given

Yes, sure.

that So, integration. triggers the X Elemer targeted protein both at lost the X And region, out is end, the – this in in be three short. frequently but that during isn’t to overlapping were that’s region RNAi ARC-XXX quite of the turns now prime transcriptome the both

of S So, preserved in and it’s in in triggers X is the that one is region other is always the the during ARO-HBV trigger almost in that upstream quite still of a but integration. DNA the part way region, that

second the that knock that gives essentially an of knock of picture. trigger we also X down was created model that it’s as model being in hypothesis that us good source taken the region trigger should that as fact best out the safely to confidence so out when of ARO-HBV and could try down So very that animal to – gave integrated X test of we even s-antigen quite the

Christopher Anzalone

And underline one know it’s Elemer call. this, you and on the to but want sure others recognize are clear I let who me to make I thing

So often It when importance that we that didn’t source discovered region integrated a ARC-XXX during both as of of luck, the know were just lost appreciate s-antigen. ARC-XXX our in by the know a integration. just is as clear, you that so DNA rotten developed had in sequences again world we wasn’t and you of we

only that’s in it downside quite DNA it works being fortuitous it gone. as turns one is going floor, still within designed, new down biological floor now part force But produced of S, us knock it the floor this we integrated so it was with right to virus. knocking left only the Now that so much actually if not whole because by to off enabled was produced but and that now course is out we can that of were cccDNA ARO-HBV that have understand and the down was ARC-XXX this

much to think will That’s with understand. so I knock that we be ARC-HBV. interesting able anyway it so And down are to – is important how see get to

Elemer Piros

very Yes, for you thank much that.

data Bruce, data, compare the XXX presented, thought the data And with the impressive if I so you that just as this mice you was was? as

Bruce Given

this trigger. we first time although So I type knock that’s purely wild indicative X ARC-XXX the model, plasmid between to say that, not model that it and out similar would for At our had that’s cccDNA. was model of created DNA new a very ARO-HBV

not We So anything we with build have did know to comparable that. didn’t ARC-XXX.

would this achieved to think look respect I very similar I but cccDNA – to ARC-XXX. transcripts, is would this with say derived what with So was

Christopher Anzalone

here S, knocking that we this in down remarks down bit and are the think and mind not gene producing so important, out has for products X are important we point And just know well to that ones we we X are some as S prepared those done antigen. is and other talking of antigen. mentioned little also Gilead knocking importance as it’s a everything think but are we real important important we our S about keep in we that interesting suggests is the work very is virus one

think X it And RNAi does down is so that its we therapy not going any that knock at parallel. to do

Elemer Piros

times also with four seven nine, Okay, the given to up Bruce point I Or or you’ve At XXX, continuous? in was think was okay. long that data term stopped? presented RNAi follow And infusions. the it what to four product was monthly entecavir

Bruce Given

used entecavir was in So these patients.

still of continuing and So ARC-XXX got you they line first are they started when today entecavir. know their dose they a

Elemer Piros

okay. Okay,

impact Okay, so on triggering those an have response. that probably didn’t

Bruce Given

really course seroclearance, which do most is the not historically they especially are to well the surface those of but where the antigenemia. for be to known nukes fall see the -- very little No the you nukes get extremely helpful part very rare, know for rare you then with And in cases respect do antigenemia antigen.

Elemer Piros

to that programs end burn clinic cash the Ken. of do just Ken, moving you’re now last you question the envision changing, with potentially Okay. the next the how into five by back And year?

Ken Myszkowski

past history burn our probably additional our CapEx was of when look $XX million year at that this it year before $XX heavier clinic. if the are we excluding million about about into So the cash spent and you we

XXXX. in to our were there some increase look clinic and see we burn cash you if the expect when at in historical So

Elemer Piros

Okay, thank you much very gentlemen.

Ken Myszkowski

Okay, thanks very much.

Operator

We are the call back closing for any further remarks. any at not showing this queue Chris questions time. turn Anzalone to to I’d like in

Christopher Anzalone

we holidays Thank we you and a new and happy all forward wish XXXX. you in seeing and you happy look year to

Operator

today’s in program This conference. Everyone Ladies the you a may your thank concludes have and disconnect. and now gentlemen, great participation day. for you

Arrowhead Pharmaceuticals (ARWR) 13 Dec 172017 Q4 Earnings call transcript